Document 0006
 DOCN  M9460006
 TI    NIH conference. Recent advances in the management of AIDS-related
       opportunistic infections.
 DT    9408
 AU    Lane HC; Laughon BE; Falloon J; Kovacs JA; Davey RT Jr; Polis MA; Masur
       H; National Institutes of Allergy and Infectious Diseases, National;
       Institutes of Health, Bethesda, MD 20892.
 SO    Ann Intern Med. 1994 Jun 1;120(11):945-55. Unique Identifier : AIDSLINE
       MED/94226434
 AB    Secondary infections remain the leading cause of death in patients with
       the acquired immunodeficiency syndrome (AIDS). Dealing with the rapidly
       evolving spectrum of infectious problems seen in patients with AIDS
       requires knowledge of current therapeutic and prophylactic strategies.
       Through an extensive preclinical trials network supported by both
       industry and government, an increasing number of new agents are being
       identified and rapidly moved into clinical trials. Several agents are
       now available to treat diseases caused by Pneumocystis carinii, and
       corticosteroids have become a useful adjunct to antimicrobial agents in
       the treatment of P. carinii pneumonia. Although the treatment of
       toxoplasmosis remains a challenge, alternatives to sulfadiazine and
       pyrimethamine are now available. Mycobacterial infections, particularly
       with Mycobacterium tuberculosis, have become an increasing problem for
       patients with AIDS, and both old and new combination drug regimens are
       being used. Cytomegalovirus disease, until recently an untreatable
       problem, can now at least be partially managed with antiviral agents.
       The use of more complete prophylactic regimens may decrease the
       morbidity and mortality from opportunistic infections.
 DE    AIDS-Related Opportunistic Infections/DRUG THERAPY/MICROBIOLOGY/
       *THERAPY  Human  National Institutes of Health (U.S.)  United States
       CONGRESS  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).